Lauretta Levati

1.2k total citations
36 papers, 947 citations indexed

About

Lauretta Levati is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Lauretta Levati has authored 36 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Lauretta Levati's work include Melanoma and MAPK Pathways (10 papers), DNA Repair Mechanisms (7 papers) and Angiogenesis and VEGF in Cancer (6 papers). Lauretta Levati is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), DNA Repair Mechanisms (7 papers) and Angiogenesis and VEGF in Cancer (6 papers). Lauretta Levati collaborates with scholars based in Italy, United States and Switzerland. Lauretta Levati's co-authors include Stefania D’Atri, Grazia Graziani, Enzo Bonmassar, Lucio Tentori, Simona Caporali, Ester Alvino, Pedro Miguel Lacal, Federica Ruffini, Gian Carlo Antonini Cappellini and Patrizia Vernole and has published in prestigious journals such as The Journal of Immunology, Cancer Research and Scientific Reports.

In The Last Decade

Lauretta Levati

35 papers receiving 933 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lauretta Levati Italy	20	699	292	279	134	94	36	947
Anna Coppa Italy	21	715 1.0×	204 0.7×	290 1.0×	75 0.6×	88 0.9×	46	998
Steve A. Maxwell United States	15	606 0.9×	225 0.8×	255 0.9×	79 0.6×	72 0.8×	23	912
Raquel Parı́s Spain	8	608 0.9×	159 0.5×	215 0.8×	101 0.8×	76 0.8×	8	836
Steven T. Sizemore United States	17	584 0.8×	186 0.6×	300 1.1×	76 0.6×	84 0.9×	33	840
Wan-Ching Yen United States	17	912 1.3×	232 0.8×	590 2.1×	131 1.0×	83 0.9×	47	1.3k
Bettina Wagenknecht Germany	18	795 1.1×	184 0.6×	270 1.0×	238 1.8×	54 0.6×	20	1.0k
Merav Yoeli-Lerner United States	7	637 0.9×	125 0.4×	182 0.7×	104 0.8×	80 0.9×	7	814
Gabriëla Wright United States	15	636 0.9×	195 0.7×	450 1.6×	268 2.0×	130 1.4×	20	1.1k
Rachelle L. Dillon United States	11	539 0.8×	158 0.5×	256 0.9×	70 0.5×	89 0.9×	18	821
Silvia Peñuelas Spain	9	648 0.9×	261 0.9×	443 1.6×	175 1.3×	69 0.7×	9	1.0k

Countries citing papers authored by Lauretta Levati

Since Specialization

Citations

This map shows the geographic impact of Lauretta Levati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauretta Levati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauretta Levati more than expected).

Fields of papers citing papers by Lauretta Levati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauretta Levati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauretta Levati. The network helps show where Lauretta Levati may publish in the future.

Co-authorship network of co-authors of Lauretta Levati

This figure shows the co-authorship network connecting the top 25 collaborators of Lauretta Levati. A scholar is included among the top collaborators of Lauretta Levati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauretta Levati. Lauretta Levati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Levati, Lauretta, Claudio Tabolacci, Antonio Facchiano, et al.. (2024). Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy. Journal of Experimental & Clinical Cancer Research. 43(1). 226–226. 3 indexed citations

Fortes, Cristina, et al.. (2024). The potential impact of dietary choices on melanoma risk: an anti-inflammatory diet. Genes & Nutrition. 19(1). 9–9.

Ruffini, Federica, Claudia Ceci, Maria Grazia Atzori, et al.. (2023). Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors. Pharmacological Research. 192. 106782–106782. 5 indexed citations

Levati, Lauretta, Cristian Bassi, Simona Mastroeni, et al.. (2022). Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy. Cancers. 14(15). 3706–3706. 7 indexed citations

Sbardella, Diego, Grazia Raffaella Tundo, Camilla Palumbo, et al.. (2022). A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose. Cell & Bioscience. 12(1). 108–108. 16 indexed citations

Tabolacci, Claudio, Martina Cordella, Sabrina Mariotti, et al.. (2021). Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals. Biomedicines. 9(1). 79–79. 13 indexed citations

Caporali, Simona, Adriana Amaro, Lauretta Levati, et al.. (2019). miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. Journal of Experimental & Clinical Cancer Research. 38(1). 272–272. 69 indexed citations

Platella, Chiara, Umberto Raucci, Nadia Rega, et al.. (2019). Shedding light on the interaction of polydatin and resveratrol with G-quadruplex and duplex DNA: a biophysical, computational and biological approach. International Journal of Biological Macromolecules. 151. 1163–1172. 35 indexed citations

Caporali, Simona, Ester Alvino, Pedro Miguel Lacal, et al.. (2016). Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. International Journal of Oncology. 49(3). 1164–1174. 56 indexed citations

10.

Graziani, Grazia, Simona Artuso, Anastasia De Luca, et al.. (2015). A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochemical Pharmacology. 95(1). 16–27. 31 indexed citations

11.

Ruffini, Federica, Grazia Graziani, Lauretta Levati, et al.. (2014). Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin. International Journal of Cancer. 136(6). E545–58. 55 indexed citations

12.

Caporali, Simona, Ester Alvino, Lauretta Levati, et al.. (2012). Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochemical Pharmacology. 84(5). 598–611. 24 indexed citations

13.

Caporali, Simona, Lauretta Levati, Grazia Graziani, et al.. (2012). NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. Journal of Translational Medicine. 10(1). 252–252. 33 indexed citations

14.

Levati, Lauretta, Elena Pagani, Sveva Romani, et al.. (2011). MicroRNA‐155 targets theSKIgene in human melanoma cell lines. Pigment Cell & Melanoma Research. 24(3). 538–550. 72 indexed citations

15.

Caporali, Simona, Ester Alvino, Giuseppe Starace, et al.. (2009). The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacological Research. 61(5). 437–448. 19 indexed citations

16.

Caporali, Simona, Lauretta Levati, Giuseppe Starace, et al.. (2008). AKT Is Activated in an Ataxia-Telangiectasia and Rad3-Related-Dependent Manner in Response to Temozolomide and Confers Protection against Drug-Induced Cell Growth Inhibition. Molecular Pharmacology. 74(1). 173–183. 64 indexed citations

17.

Tentori, Lucio, Ilaria Portarena, Marcella Barbarino, et al.. (2003). Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor. Molecular Pharmacology. 63(1). 192–202. 30 indexed citations

18.

Tentori, Lucio, Adriana Balduzzi, Ilaria Portarena, et al.. (2001). Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death and Differentiation. 8(8). 817–828. 34 indexed citations

19.

Tentori, Lucio, Mario Turriziani, Annalucia Serafino, et al.. (1999). Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia. 13(6). 901–909. 45 indexed citations

20.

Levati, Lauretta, Giancarlo Marra, Teresa Lettieri, et al.. (1998). Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T‐cell leukemia line tolerant to methylating agents. Genes Chromosomes and Cancer. 23(2). 159–166. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact